← All trials
NCT04435288
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2020
- Primary completion
- Jul 1, 2022
- Completion date
- May 31, 2026
- First posted
- Jun 17, 2020
- Last posted
- Jun 17, 2020
- Enrollment
- 112
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Ghent UniversityLead sponsor
- Universitair Ziekenhuis GentOverall official - principal investigator
- Ghent UniversityOverall official - principal investigator
- MerckCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.